Flagship Ventures Management

Latest statistics and disclosures from Flagship Pioneering's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are MRNA, MCRB, KLDO, DNLI, RUBY, and represent 94.35% of Flagship Pioneering's stock portfolio.
  • Reduced shares in these 2 stocks: MRNA (-$637M), DNLI (-$72M).
  • Flagship Pioneering was a net seller of stock by $-708M.
  • Flagship Pioneering has $3.6B in assets under management (AUM), dropping by 5.18%.

Tip: Access up to 7 years of quarterly data

Positions held by Flagship Ventures Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Flagship Pioneering

Companies in the Flagship Pioneering portfolio as of the September 2020 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Moderna (MRNA) 60.3 $2.2B -22% 31M 70.75
Seres Therapeutics (MCRB) 16.9 $611M 22M 28.31
Kaleido Biosciences Ord (KLDO) 5.9 $214M 19M 11.07
Denali Therapeutics (DNLI) 5.9 $214M -25% 6.0M 35.83
Rubius Therapeutics (RUBY) 5.3 $192M 38M 5.01
Evelo Biosciences (EVLO) 3.3 $121M 23M 5.27
Axcella Health Inc equity (AXLA) 1.6 $58M 13M 4.62
Syros Pharmaceuticals (SYRS) 0.7 $26M 2.9M 8.84

Past Filings by Flagship Pioneering

SEC 13F filings are viewable for Flagship Pioneering going back to 2016